AI in Drug Discovery Xchange - Boston 2026

ABOUT THE EVENT

Date: Wednesday, May 6, 2026 8am–5:45pm EDT
Event Location: Boston, Massachusetts

hubXchange’s AI in Drug Discovery Xchange Boston 2026 brings together senior-level scientists, R&D leaders, and executives from top pharmaceutical and biotechnology companies to explore the transformative power of artificial intelligence in drug discovery. This one-day forum is designed to foster open collaboration and deep insights, combining expert presentations, roundtable discussions, 1:1 meetings, poster sessions, and dedicated networking time.

Attendees will dive into critical topics such as:

  • Data quality and curation for AI/ML in drug development

  • AI-driven target identification and validation

  • Lead generation and optimization using computational models

  • Predictive modelling for drug response and efficacy

  • Structure-based drug design, virtual screening, and AI-guided small molecule development

With leading industry experts and innovators sharing their latest advances, you’ll gain a broad view of how AI is reshaping every stage of the drug discovery pipeline — from early research to candidate selection and optimization. The format encourages active engagement, discussion, and collaboration rather than passive listening, making it ideal for decision-makers, scientists, and teams looking to integrate AI strategies into their workflows.

Location & Date: Boston, MA — May 6, 2026
Registration is Complimentary! Book early to secure your place.

MORE EVENTS
In this webinar, leading oncology experts Dr. Javier Cortés and Dr. Antonio Llombart-Cussac will explore how collaborative-initiated trials are transforming the clinical research landscape and creating new opportunities for scientific and clinical impact.
Monday, March 2, 2026 11am–12pm EST
 · 
Virtual
Artificial intelligence is rapidly reshaping the life sciences, from automating repetitive tasks to enabling advanced scientific and safety assessments across drugs, biologics, and devices. As adoption grows across regulators, pharmaceutical companies, technology developers, nonprofits, and collaborative consortia, the need for clear, risk-based frameworks for validation, governance and human oversight becomes increasingly critical.
Tuesday, March 17, 2026 1–2pm EDT
 · 
Virtual
Every biopharma R&D and investment decision could be guided by connected intelligence. Join us to hear firsthand how agentic workflows and enterprise-scale data are helping drug developers move faster from molecule to market with greater confidence.
Wednesday, March 18, 2026 11am–12pm EDT
 · 
Virtual